Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Peter van Tintelen

Showing results (171-180 of 232) with videos related to

Pageof 24
Sort By:
Circulation. Genomic and Precision Medicine|December 17, 2024
Recreational and Occupational Physical Activity and Risk of Adverse Events in Truncating <i>MYBPC3</i> Founder Variant CarriersFahima Hassanzada, Mark Jansen, Freyja H M van Lint, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|April 1, 2024
Long-term reliability of the phospholamban (PLN) p.(Arg14del) risk model in predicting major ventricular arrhythmia: a landmark studyMyrthe Y C van der Heide, Tom E Verstraelen, Freyja H M van Lint, et al.
Heart Rhythm|February 25, 2024
ECG-only explainable deep learning algorithm predicts the risk for malignant ventricular arrhythmia in phospholamban cardiomyopathyRutger R van de Leur, Remco de Brouwer, Hidde Bleijendaal, et al.
Journal of Medical Genetics|September 9, 2019
Homozygous damaging SOD2 variant causes lethal neonatal dilated cardiomyopathyRowida Almomani, Johanna C Herkert, Anna Posafalvi, et al.
Journal of the American College of Cardiology|June 30, 2007
Severe myocardial fibrosis caused by a deletion of the 5' end of the lamin A/C geneJ Peter van Tintelen, Rene A Tio, Wilhelmina S Kerstjens-Frederikse, et al.
Circulation. Cardiovascular Genetics|December 25, 2009
Desmoglein-2 and desmocollin-2 mutations in dutch arrhythmogenic right ventricular dysplasia/cardiomypathy patients: results from a multicenter studyZahurul A Bhuiyan, Jan D H Jongbloed, Jasper van der Smagt, et al.
European Heart Journal|August 25, 2023
2023 ESC Guidelines for the management of cardiomyopathiesElena Arbelo, Alexandros Protonotarios, Juan R Gimeno, et al.
Circulation. Genomic and Precision Medicine|February 10, 2021
Cadherin 2-Related Arrhythmogenic Cardiomyopathy: Prevalence and Clinical FeaturesAlice Ghidoni, Perry M Elliott, Petros Syrris, et al.
European Journal of Heart Failure|November 5, 2016
Truncating titin mutations are associated with a mild and treatable form of dilated cardiomyopathyJoeri A Jansweijer, Karin Nieuwhof, Francesco Russo, et al.
The American Journal of Cardiology|July 23, 2013
Arrhythmogenic right ventricular dysplasia/cardiomyopathy according to revised 2010 task force criteria with inclusion of non-desmosomal phospholamban mutation carriersJudith A Groeneweg, Paul A van der Zwaag, Louise R A Olde Nordkamp, et al.
Pageof 24

Showing results (171-180 of 232) with videos related to

Sort By:
Pageof 24
Circulation. Genomic and Precision Medicine|December 17, 2024
Recreational and Occupational Physical Activity and Risk of Adverse Events in Truncating <i>MYBPC3</i> Founder Variant CarriersFahima Hassanzada, Mark Jansen, Freyja H M van Lint, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|April 1, 2024
Long-term reliability of the phospholamban (PLN) p.(Arg14del) risk model in predicting major ventricular arrhythmia: a landmark studyMyrthe Y C van der Heide, Tom E Verstraelen, Freyja H M van Lint, et al.
Heart Rhythm|February 25, 2024
ECG-only explainable deep learning algorithm predicts the risk for malignant ventricular arrhythmia in phospholamban cardiomyopathyRutger R van de Leur, Remco de Brouwer, Hidde Bleijendaal, et al.
Journal of Medical Genetics|September 9, 2019
Homozygous damaging SOD2 variant causes lethal neonatal dilated cardiomyopathyRowida Almomani, Johanna C Herkert, Anna Posafalvi, et al.
Journal of the American College of Cardiology|June 30, 2007
Severe myocardial fibrosis caused by a deletion of the 5' end of the lamin A/C geneJ Peter van Tintelen, Rene A Tio, Wilhelmina S Kerstjens-Frederikse, et al.
Circulation. Cardiovascular Genetics|December 25, 2009
Desmoglein-2 and desmocollin-2 mutations in dutch arrhythmogenic right ventricular dysplasia/cardiomypathy patients: results from a multicenter studyZahurul A Bhuiyan, Jan D H Jongbloed, Jasper van der Smagt, et al.
European Heart Journal|August 25, 2023
2023 ESC Guidelines for the management of cardiomyopathiesElena Arbelo, Alexandros Protonotarios, Juan R Gimeno, et al.
Circulation. Genomic and Precision Medicine|February 10, 2021
Cadherin 2-Related Arrhythmogenic Cardiomyopathy: Prevalence and Clinical FeaturesAlice Ghidoni, Perry M Elliott, Petros Syrris, et al.
European Journal of Heart Failure|November 5, 2016
Truncating titin mutations are associated with a mild and treatable form of dilated cardiomyopathyJoeri A Jansweijer, Karin Nieuwhof, Francesco Russo, et al.
The American Journal of Cardiology|July 23, 2013
Arrhythmogenic right ventricular dysplasia/cardiomyopathy according to revised 2010 task force criteria with inclusion of non-desmosomal phospholamban mutation carriersJudith A Groeneweg, Paul A van der Zwaag, Louise R A Olde Nordkamp, et al.
Pageof 24